What is Veritas Genetics?
Veritas Genetics operates as a global pioneer in the consumer genomics sector, dedicated to removing traditional barriers to genetic screening. By providing accessible, actionable genetic insights to individuals, physicians, and medical researchers, the company facilitates a shift toward proactive, personalized medicine. Recognized by MIT Technology Review as one of the world's smartest companies, Veritas leverages its deep roots in Harvard Medical School research to bridge the gap between complex genomic data and practical lifestyle or clinical decision-making. Its market position is defined by a commitment to high-quality, scalable sequencing services that empower patients to manage their long-term health outcomes with precision.
How much funding has Veritas Genetics raised?
Veritas Genetics has raised a total of $48.3M across 6 funding rounds:
Series A
$12M
Series B
$23.9M
Private Equity
$1.7M
Private Equity
$9.7M
Debt
$150K
Debt
$854K
Series A (2015): $12M, investors not publicly disclosed
Series B (2016): $23.9M led by Jiangsu Simcere Pharmaceutical, Lilly Asia Ventures, and Trustbridge Partners
Private Equity (2017): $1.7M, investors not publicly disclosed
Private Equity (2018): $9.7M featuring PHILAB Holdings Corp
Debt (2020): $150K backed by PPP
Debt (2021): $854K with participation from PPP
Key Investors in Veritas Genetics
Jiangsu Simcere Pharmaceutical
A pharmaceutical innovator focused on oncology, neurology, and autoimmune diseases, dedicated to developing advanced therapeutic options through global research collaborations.
Lilly Asia Ventures
A premier biomedical venture capital firm that partners with exceptional entrepreneurs to build companies developing breakthrough products for human health.
Trustbridge Partners
A leading growth equity investor managing significant assets with a focus on high-quality opportunities in the TMT, consumer, and healthcare sectors.
What's next for Veritas Genetics?
Looking ahead, Veritas Genetics is poised to leverage its recent strategic investment to deepen its penetration into global healthcare markets. The company's roadmap likely involves the integration of artificial intelligence to interpret complex genomic datasets at scale, further reducing the cost of whole genome sequencing for the average consumer. By maintaining its focus on clinical-grade accuracy and user-centric design, Veritas is well-positioned to lead the next wave of precision medicine. The firm's ongoing expansion efforts, supported by its diverse investor base, suggest a continued focus on strategic partnerships with pharmaceutical entities and healthcare providers to standardize genetic screening as a fundamental component of preventative care.
See full Veritas Genetics company page
